Feasibility and acceptability of extending seasonal malaria chemoprevention to children aged 5–10 years
Published:
Resources: Research brief
This study aimed to understand the barriers to delivering SMC in Massaguet district, Chad, to children above 59 months.
Malaria is endemic in Chad, with a prevalence of around 41 percent in 2017. The World Health Organization recommends seasonal malaria chemoprevention (SMC) for children 3–59 months in areas of highly seasonal transmission across the Sahel. Routine household surveys conducted to evaluate coverage and quality of SMC delivery in Chad found that sulfadoxine-pyrimethamine and amodiaquine administration to children over 59 months appears to be common.
